LGVN vs. VINC, BCLI, LSTA, PLUR, DRRX, ASMB, CMRX, SCYX, PMVP, and MIST
Should you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include Vincerx Pharma (VINC), Brainstorm Cell Therapeutics (BCLI), Lisata Therapeutics (LSTA), Pluri (PLUR), DURECT (DRRX), Assembly Biosciences (ASMB), Chimerix (CMRX), SCYNEXIS (SCYX), PMV Pharmaceuticals (PMVP), and Milestone Pharmaceuticals (MIST). These companies are all part of the "medical" sector.
Vincerx Pharma (NASDAQ:VINC) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, community ranking, valuation, risk and institutional ownership.
In the previous week, Vincerx Pharma and Vincerx Pharma both had 2 articles in the media. Longeveron's average media sentiment score of 1.44 beat Vincerx Pharma's score of 0.29 indicating that Vincerx Pharma is being referred to more favorably in the media.
Vincerx Pharma received 12 more outperform votes than Longeveron when rated by MarketBeat users. However, 88.89% of users gave Longeveron an outperform vote while only 64.52% of users gave Vincerx Pharma an outperform vote.
Vincerx Pharma has a net margin of 0.00% compared to Vincerx Pharma's net margin of -2,129.24%. Longeveron's return on equity of -261.83% beat Vincerx Pharma's return on equity.
44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 22.9% of Vincerx Pharma shares are held by company insiders. Comparatively, 19.1% of Longeveron shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Longeveron has higher revenue and earnings than Vincerx Pharma. Vincerx Pharma is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.
Vincerx Pharma has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.
Vincerx Pharma currently has a consensus price target of $5.00, suggesting a potential upside of 635.29%. Longeveron has a consensus price target of $12.00, suggesting a potential upside of 248.84%. Given Longeveron's higher probable upside, analysts plainly believe Vincerx Pharma is more favorable than Longeveron.
Summary
Vincerx Pharma beats Longeveron on 10 of the 14 factors compared between the two stocks.
Get Longeveron News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Longeveron Competitors List
Related Companies and Tools
